Prequenza pushes Intervet to the top

Less than one year on from the launch of Equilis^® Prequenza and Equilis^® Prequenza Te, Intervet UK’s share of the equine flu vaccine market has rocketed to 40% - 10 percentage points clear of its nearest competitor.

The figures, based on industry sales data in September 2007, mean that Intervet has now become overall market leader in equine vaccines in both the UK and throughout Europe during the same period.

With vets embracing Equilis Prequenza and Equilis Prequenza Te’s modern ISCOM-Matrix^®  delivery system, which leaves no depot at the site of injection, the vaccines are the only ones proven under challenge to help protect against the most recent ‘flu strains, A/equi 2/South Africa/04/03 and A/equi 2/Newmarket/05/03.

Tim Zoch, senior product manager at Intervet UK comments: “Our market leader status is indicative of our commitment to the equine sector.  We have undertaken considerable research and development, resulting in a series of strong recent product launches including Dolorex^® and Cephaguard^® IV as well as the Prequenza range.  In addition, we’re helping build the sector with our practice development initiatives, Chameleon and equine e-booster.”

For further information on Intervet’s range of equine products, please contact your account manager or visit www.intervet.co.uk.